OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: University of Exeter

1 Projects | 1 Researchers | $3,024,684 Invested

2020

University of Exeter

Clive Ballard, MB ChB (Medicine), MMed Sci, M.R.C.Psych, MD.

A Placebo Controlled, Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Mild Cognitive Impairment Due to Alzheimer’s Disease, Nested within a Multi-Arm Phase 2 Clinical Trial Platform

  • Funding Amount: $3,024,684
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Active